{"meta":{"status":200,"messages":[],"pagination":{"max":1,"offset":0,"count":1,"total":1,"pageNum":1,"totalPages":1,"sort":null,"currentUrl":"https://api.digitalmedia.hhs.gov/api/v2/resources/media.json?offset=0&max=1&ignoreHiddenMedia=1&format=json&id=1736&newUrlBase=https://www.cancer.gov/node/14381/","nextUrl":null,"previousUrl":null}},"results":[{"content":"<body>\n <div class=\"syndicate\"> \n  <!-- ********************************* BEGIN Page Content ********************************** --> \n  <h1 autofocus=\"true\">Surgery to Reduce the Risk of Breast Cancer</h1> \n  <div> \n   <nav role=\"navigation\"> \n    <h2>On This Page</h2> \n    <ul> \n     <li> <a href=\"#can-surgery-be-used-to-reduce-someones-risk-of-breast-cancer\"> <p>Can surgery be used to reduce someone\u2019s risk of breast cancer?</p></a> </li> \n     <li> <a href=\"#how-effective-is-risk-reducing-mastectomy\"> <p>How effective is risk-reducing mastectomy?</p></a> </li> \n     <li> <a href=\"#who-should-consider-having-surgery-to-reduce-their-risk-of-breast-cancer\"> <p>Who should consider having surgery to reduce their risk of breast cancer?</p></a> </li> \n     <li> <a href=\"#can-a-person-have-risk-reducing-surgery-if-they-have-already-been-diagnosed-with-breast-cancer\"> <p>Can a person have risk-reducing surgery if they have already been diagnosed with breast cancer?</p></a> </li> \n     <li> <a href=\"#what-are-the-potential-harms-of-risk-reducing-surgeries\"> <p>What are the potential harms of risk-reducing surgeries?</p></a> </li> \n     <li> <a href=\"#what-can-someone-at-very-high-risk-of-breast-cancer-do-if-they-do-not-want-to-undergo-risk-reducing-surgery\"> <p>What can someone at very high risk of breast cancer do if they do not want to undergo risk-reducing surgery?</p></a> </li> \n     <li> <a href=\"#what-can-people-at-very-high-risk-of-ovarian-cancer-do-to-reduce-their-risk\"> <p>What can people at very high risk of ovarian cancer do to reduce their risk?&nbsp;</p></a> </li> \n     <li> <a href=\"#does-health-insurance-cover-the-cost-of-risk-reducing-surgery\"> <p>Does health insurance cover the cost of risk-reducing surgery?</p></a> </li> \n     <li> <a href=\"#who-should-a-person-talk-to-when-considering-surgery-to-reduce-their-risk-of-breast-cancer\"> <p>Who should a person talk to when considering surgery to reduce their risk of breast cancer?</p></a> </li> \n    </ul> \n   </nav> \n   <div> \n    <section itemscope=\"\" itemprop=\"mainEntity\" itemtype=\"https://schema.org/Question\" aria-labelledby=\"can-surgery-be-used-to-reduce-someones-risk-of-breast-cancer\"> \n     <h2 itemprop=\"name\"> <p>Can surgery be used to reduce someone\u2019s risk of breast cancer?</p> </h2> \n     <div itemscope itemprop=\"acceptedAnswer\" itemtype=\"https://schema.org/Answer\"> \n      <div itemprop=\"text\"> \n       <p>Yes. Risk-reducing (also called preventive or <a data-gloss-id=\"256574\" data-gloss-dictionary=\"Cancer.gov\" data-gloss-audience=\"Patient\" data-gloss-lang=\"en\" href=\"https://www.cancer.gov/publications/dictionaries/cancer-terms/def/256574\">prophylactic</a>) surgery can lower the risk of breast cancer in people who are at very high risk, such as women who carry a harmful mutation in a breast <a data-gloss-id=\"806204\" data-gloss-dictionary=\"Cancer.gov\" data-gloss-audience=\"Patient\" data-gloss-lang=\"en\" href=\"https://www.cancer.gov/publications/dictionaries/cancer-terms/def/806204\">cancer susceptibility gene</a> such as <a data-gloss-id=\"46047\" data-gloss-dictionary=\"Cancer.gov\" data-gloss-audience=\"Patient\" data-gloss-lang=\"en\" href=\"https://www.cancer.gov/publications/dictionaries/cancer-terms/def/46047\"><em>BRCA1</em></a>, <a data-gloss-id=\"46742\" data-gloss-dictionary=\"Cancer.gov\" data-gloss-audience=\"Patient\" data-gloss-lang=\"en\" href=\"https://www.cancer.gov/publications/dictionaries/cancer-terms/def/46742\"><em>BRCA2</em></a>, <a data-gloss-id=\"796656\" data-gloss-dictionary=\"Cancer.gov\" data-gloss-audience=\"Patient\" data-gloss-lang=\"en\" href=\"https://www.cancer.gov/publications/dictionaries/cancer-terms/def/796656\"><em>TP53</em></a>, or <a data-gloss-id=\"653138\" data-gloss-dictionary=\"Cancer.gov\" data-gloss-audience=\"Patient\" data-gloss-lang=\"en\" href=\"https://www.cancer.gov/publications/dictionaries/cancer-terms/def/653138\"><em>PTEN</em></a>.&nbsp;</p> \n       <p>The main type of surgery to reduce breast cancer risk is the removal of both breasts, called <strong>bilateral risk-reducing mastectomy</strong> (or <a data-gloss-id=\"304724\" data-gloss-dictionary=\"Cancer.gov\" data-gloss-audience=\"Patient\" data-gloss-lang=\"en\" href=\"https://www.cancer.gov/publications/dictionaries/cancer-terms/def/304724\"><strong>bilateral prophylactic mastectomy</strong></a>). The surgery may be a total mastectomy, in which the nipple and areola are removed, or a nipple-sparing mastectomy, which preserves the nipple and areola. Total mastectomy provides slightly more risk reduction, whereas nipple-sparing mastectomy allows for more natural-looking breasts after breast reconstruction surgery (<a href=\"#r1\">1</a>). &nbsp;</p> \n       <p>A second type of risk-reducing surgery is the removal of both ovaries (<strong>bilateral </strong><a data-gloss-id=\"44932\" data-gloss-dictionary=\"Cancer.gov\" data-gloss-audience=\"Patient\" data-gloss-lang=\"en\" href=\"https://www.cancer.gov/publications/dictionaries/cancer-terms/def/44932\"><strong>prophylactic oophorectomy</strong></a>) or of the ovaries and the <a data-gloss-id=\"45687\" data-gloss-dictionary=\"Cancer.gov\" data-gloss-audience=\"Patient\" data-gloss-lang=\"en\" href=\"https://www.cancer.gov/publications/dictionaries/cancer-terms/def/45687\">fallopian tubes</a> (<strong>bilateral prophylactic </strong><a data-gloss-id=\"46569\" data-gloss-dictionary=\"Cancer.gov\" data-gloss-audience=\"Patient\" data-gloss-lang=\"en\" href=\"https://www.cancer.gov/publications/dictionaries/cancer-terms/def/46569\"><strong>salpingo-oophorectomy</strong></a>, also called <strong>risk-reducing salpingo-oophorectomy</strong>). This surgery is often used to reduce the risk of ovarian and fallopian tube cancer in those who are at high risk for the disease because of inherited harmful changes in&nbsp;<em>BRCA1</em>, <em>BRCA2</em>, and several other genes. Some studies have suggested that risk-reducing salpingo-oophorectomy also reduces the risk of breast cancer in women at high risk, but other studies have not shown such a reduction (<a href=\"#r2\">2</a>\u2013<a href=\"#r5\">5</a>).</p> \n      </div> \n     </div> \n    </section> \n    <section itemscope=\"\" itemprop=\"mainEntity\" itemtype=\"https://schema.org/Question\" aria-labelledby=\"how-effective-is-risk-reducing-mastectomy\"> \n     <h2 itemprop=\"name\"> <p>How effective is risk-reducing mastectomy?</p> </h2> \n     <div itemscope itemprop=\"acceptedAnswer\" itemtype=\"https://schema.org/Answer\"> \n      <div itemprop=\"text\"> \n       <p><a data-gloss-id=\"304724\" data-gloss-dictionary=\"Cancer.gov\" data-gloss-audience=\"Patient\" data-gloss-lang=\"en\" href=\"https://www.cancer.gov/publications/dictionaries/cancer-terms/def/304724\">Bilateral mastectomy</a> has been shown to reduce the risk of breast cancer by at least 95% in women who have a harmful (disease-causing) variant in the <a data-gloss-id=\"46047\" data-gloss-dictionary=\"Cancer.gov\" data-gloss-audience=\"Patient\" data-gloss-lang=\"en\" href=\"https://www.cancer.gov/publications/dictionaries/cancer-terms/def/46047\"><em>BRCA1</em></a> gene or the <a data-gloss-id=\"46742\" data-gloss-dictionary=\"Cancer.gov\" data-gloss-audience=\"Patient\" data-gloss-lang=\"en\" href=\"https://www.cancer.gov/publications/dictionaries/cancer-terms/def/46742\"><em>BRCA2</em></a> gene and up to 90% in women who have a strong <a data-gloss-id=\"302456\" data-gloss-dictionary=\"Cancer.gov\" data-gloss-audience=\"Patient\" data-gloss-lang=\"en\" href=\"https://www.cancer.gov/publications/dictionaries/cancer-terms/def/302456\">family history</a> of breast cancer (<a href=\"#r6\">6</a>\u2013<a href=\"#r9\">9</a>). (It is important to keep in mind that mastectomy is not 100% effective at reducing risk because it is impossible to remove all the breast tissue that may be at risk of becoming cancerous in the future.)</p> \n      </div> \n     </div> \n    </section> \n    <section itemscope=\"\" itemprop=\"mainEntity\" itemtype=\"https://schema.org/Question\" aria-labelledby=\"who-should-consider-having-surgery-to-reduce-their-risk-of-breast-cancer\"> \n     <h2 itemprop=\"name\"> <p>Who should consider having surgery to reduce their risk of breast cancer?</p> </h2> \n     <div itemscope itemprop=\"acceptedAnswer\" itemtype=\"https://schema.org/Answer\"> \n      <div itemprop=\"text\"> \n       <p>People who are known to have inherited a <a data-gloss-id=\"460144\" data-gloss-dictionary=\"Cancer.gov\" data-gloss-audience=\"Patient\" data-gloss-lang=\"en\" href=\"https://www.cancer.gov/publications/dictionaries/cancer-terms/def/460144\">harmful mutation</a>&nbsp;that greatly increases their risk of developing breast cancer may consider having <a data-gloss-id=\"304724\" data-gloss-dictionary=\"Cancer.gov\" data-gloss-audience=\"Patient\" data-gloss-lang=\"en\" href=\"https://www.cancer.gov/publications/dictionaries/cancer-terms/def/304724\">bilateral risk-reducing mastectomy</a> to reduce this risk.&nbsp;</p> \n       <p>People who have a high risk of breast cancer but are not known to have inherited a harmful mutation may want to discuss with their doctors the possible benefits and harms of risk-reducing mastectomy in their situation. Such people include those with <a data-gloss-id=\"800904\" data-gloss-dictionary=\"Cancer.gov\" data-gloss-audience=\"Patient\" data-gloss-lang=\"en\" href=\"https://www.cancer.gov/publications/dictionaries/cancer-terms/def/800904\">pleomorphic lobular carcinoma in situ</a> (PLCIS) plus a strong <a data-gloss-id=\"302456\" data-gloss-dictionary=\"Cancer.gov\" data-gloss-audience=\"Patient\" data-gloss-lang=\"en\" href=\"https://www.cancer.gov/publications/dictionaries/cancer-terms/def/302456\">family history</a> of breast cancer and those who have had <a data-gloss-id=\"44971\" data-gloss-dictionary=\"Cancer.gov\" data-gloss-audience=\"Patient\" data-gloss-lang=\"en\" href=\"https://www.cancer.gov/publications/dictionaries/cancer-terms/def/44971\">radiation therapy</a> to the chest (including the breasts) before age 30 years.</p> \n      </div> \n     </div> \n    </section> \n    <section itemscope=\"\" itemprop=\"mainEntity\" itemtype=\"https://schema.org/Question\" aria-labelledby=\"can-a-person-have-risk-reducing-surgery-if-they-have-already-been-diagnosed-with-breast-cancer\"> \n     <h2 itemprop=\"name\"> <p>Can a person have risk-reducing surgery if they have already been diagnosed with breast cancer?</p> </h2> \n     <div itemscope itemprop=\"acceptedAnswer\" itemtype=\"https://schema.org/Answer\"> \n      <div itemprop=\"text\"> \n       <p>Yes. Some people who have been diagnosed with cancer in one breast, particularly those who are known to be at very high risk, may consider having the other breast (called the <a data-gloss-id=\"44169\" data-gloss-dictionary=\"Cancer.gov\" data-gloss-audience=\"Patient\" data-gloss-lang=\"en\" href=\"https://www.cancer.gov/publications/dictionaries/cancer-terms/def/44169\">contralateral</a> breast) removed as well, even if there is no sign of cancer in that breast. Removal of the contralateral breast during breast cancer surgery (known as <a data-gloss-id=\"803190\" data-gloss-dictionary=\"Cancer.gov\" data-gloss-audience=\"Patient\" data-gloss-lang=\"en\" href=\"https://www.cancer.gov/publications/dictionaries/cancer-terms/def/803190\">contralateral prophylactic mastectomy</a>) reduces the risk of breast cancer in that breast (<a href=\"#r1\">1</a>,<a href=\"#r6\">6</a>,<a href=\"#r8\">8</a>,<a href=\"#r9\">9</a>).&nbsp;</p> \n       <p>However, doctors often discourage contralateral prophylactic mastectomy for people with cancer in one breast who do not have a high risk of developing a contralateral breast cancer. That is because their risk of developing another breast cancer, either in the same or the other breast, is very small (<a href=\"#r10\">10</a>), especially if their treatment included <a data-gloss-id=\"815291\" data-gloss-dictionary=\"Cancer.gov\" data-gloss-audience=\"Patient\" data-gloss-lang=\"en\" href=\"https://www.cancer.gov/publications/dictionaries/cancer-terms/def/815291\">adjuvant chemotherapy</a> or <a data-gloss-id=\"45110\" data-gloss-dictionary=\"Cancer.gov\" data-gloss-audience=\"Patient\" data-gloss-lang=\"en\" href=\"https://www.cancer.gov/publications/dictionaries/cancer-terms/def/45110\">hormone therapy</a> (<a href=\"#r11\">11</a>,<a href=\"#r12\">12</a>). Contralateral mastectomy may also increase the risk of complications and could result in delays in treatment for the known cancer. Moreover, the evidence to date does not indicate that contralateral prophylactic mastectomy reduces <a data-gloss-id=\"496502\" data-gloss-dictionary=\"Cancer.gov\" data-gloss-audience=\"Patient\" data-gloss-lang=\"en\" href=\"https://www.cancer.gov/publications/dictionaries/cancer-terms/def/496502\">mortality</a>. &nbsp;</p> \n       <p>People with a harmful BRCA variant who have surgery to treat breast cancer may also consider having risk-reducing <a data-gloss-id=\"46569\" data-gloss-dictionary=\"Cancer.gov\" data-gloss-audience=\"Patient\" data-gloss-lang=\"en\" href=\"https://www.cancer.gov/publications/dictionaries/cancer-terms/def/46569\">salpingo-oophorectomy</a> to improve their long-term outcomes. The risk of dying from any cause after breast cancer surgery for patients with a BRCA variant was reduced by more than half if they also received prophylactic salpingo-oophorectomy (<a href=\"#r13\">13</a>). The risk reduction was greater for those with a harmful variant in <a data-gloss-id=\"46047\" data-gloss-dictionary=\"Cancer.gov\" data-gloss-audience=\"Patient\" data-gloss-lang=\"en\" href=\"https://www.cancer.gov/publications/dictionaries/cancer-terms/def/46047\"><em>BRCA1</em></a> than for those with a harmful variant in <a data-gloss-id=\"46742\" data-gloss-dictionary=\"Cancer.gov\" data-gloss-audience=\"Patient\" data-gloss-lang=\"en\" href=\"https://www.cancer.gov/publications/dictionaries/cancer-terms/def/46742\"><em>BRCA2</em></a>.</p> \n      </div> \n     </div> \n    </section> \n    <section itemscope=\"\" itemprop=\"mainEntity\" itemtype=\"https://schema.org/Question\" aria-labelledby=\"what-are-the-potential-harms-of-risk-reducing-surgeries\"> \n     <h2 itemprop=\"name\"> <p>What are the potential harms of risk-reducing surgeries?</p> </h2> \n     <div itemscope itemprop=\"acceptedAnswer\" itemtype=\"https://schema.org/Answer\"> \n      <div itemprop=\"text\"> \n       <p>As with any other major surgery, <a data-gloss-id=\"304724\" data-gloss-dictionary=\"Cancer.gov\" data-gloss-audience=\"Patient\" data-gloss-lang=\"en\" href=\"https://www.cancer.gov/publications/dictionaries/cancer-terms/def/304724\">bilateral prophylactic mastectomy</a> and bilateral prophylactic <a data-gloss-id=\"46569\" data-gloss-dictionary=\"Cancer.gov\" data-gloss-audience=\"Patient\" data-gloss-lang=\"en\" href=\"https://www.cancer.gov/publications/dictionaries/cancer-terms/def/46569\">salpingo-oophorectomy</a> have potential complications or harms, such as bleeding or infection (<a href=\"#r14\">14</a>). Also, both surgeries are irreversible.&nbsp;</p> \n       <p>Breast removal can also affect psychological well-being due to a change in <a data-gloss-id=\"450092\" data-gloss-dictionary=\"Cancer.gov\" data-gloss-audience=\"Patient\" data-gloss-lang=\"en\" href=\"https://www.cancer.gov/publications/dictionaries/cancer-terms/def/450092\">body image</a> and the loss of normal breast functions. Although most people who choose to have this surgery are satisfied with their decision, they can still experience anxiety and concerns about body image (<a href=\"#r15\">15</a>,<a href=\"#r16\">16</a>). People who undergo total mastectomies lose nipple sensation, which may hinder sexual arousal.</p> \n       <p>The sudden drop in estrogen production caused by bilateral prophylactic salpingo-oophorectomy induces <a data-gloss-id=\"449953\" data-gloss-dictionary=\"Cancer.gov\" data-gloss-audience=\"Patient\" data-gloss-lang=\"en\" href=\"https://www.cancer.gov/publications/dictionaries/cancer-terms/def/449953\">early menopause</a> (this is also called surgical menopause). The abrupt onset of menopausal symptoms, including hot flashes, insomnia, anxiety, and depression, can be distressing.&nbsp;</p> \n       <p>People who have severe menopausal symptoms after undergoing bilateral prophylactic salpingo-oophorectomy may consider using short-term <a data-gloss-id=\"304725\" data-gloss-dictionary=\"Cancer.gov\" data-gloss-audience=\"Patient\" data-gloss-lang=\"en\" href=\"https://www.cancer.gov/publications/dictionaries/cancer-terms/def/304725\">menopausal hormone therapy</a> after surgery to alleviate these symptoms. Learn more about <a href=\"https://www.cancer.gov/about-cancer/causes-prevention/risk/hormones/mht-fact-sheet#what-are-the-health-effectsof-menopausal-hormone-therapy\">the health effects of menopausal hormone therapy</a>.</p> \n      </div> \n     </div> \n    </section> \n    <section itemscope=\"\" itemprop=\"mainEntity\" itemtype=\"https://schema.org/Question\" aria-labelledby=\"what-can-someone-at-very-high-risk-of-breast-cancer-do-if-they-do-not-want-to-undergo-risk-reducing-surgery\"> \n     <h2 itemprop=\"name\"> <p>What can someone at very high risk of breast cancer do if they do not want to undergo risk-reducing surgery?</p> </h2> \n     <div itemscope itemprop=\"acceptedAnswer\" itemtype=\"https://schema.org/Answer\"> \n      <div itemprop=\"text\"> \n       <p>Options for some people who are at very high risk of breast cancer (or of <a data-gloss-id=\"44169\" data-gloss-dictionary=\"Cancer.gov\" data-gloss-audience=\"Patient\" data-gloss-lang=\"en\" href=\"https://www.cancer.gov/publications/dictionaries/cancer-terms/def/44169\">contralateral</a> breast cancer, if they have previously been treated for breast cancer) and wish to avoid risk-reducing surgery include:</p> \n       <ul> \n        <li><strong>More frequent breast cancer screening (also called enhanced surveillance).</strong> For example, they may have yearly <a data-gloss-id=\"45775\" data-gloss-dictionary=\"Cancer.gov\" data-gloss-audience=\"Patient\" data-gloss-lang=\"en\" href=\"https://www.cancer.gov/publications/dictionaries/cancer-terms/def/45775\">mammograms</a> and yearly <a data-gloss-id=\"45997\" data-gloss-dictionary=\"Cancer.gov\" data-gloss-audience=\"Patient\" data-gloss-lang=\"en\" href=\"https://www.cancer.gov/publications/dictionaries/cancer-terms/def/45997\">magnetic resonance imaging</a> (MRI) screening\u2014with these tests staggered so that the breasts are imaged every 6 months\u2014as well as <a data-gloss-id=\"304715\" data-gloss-dictionary=\"Cancer.gov\" data-gloss-audience=\"Patient\" data-gloss-lang=\"en\" href=\"https://www.cancer.gov/publications/dictionaries/cancer-terms/def/304715\">clinical breast examinations</a> performed regularly by a health care professional (<a href=\"#r17\">17</a>).</li> \n        <li><strong>Risk-reducing medications (sometimes called chemoprevention).</strong> <a data-gloss-id=\"509341\" data-gloss-dictionary=\"Cancer.gov\" data-gloss-audience=\"Patient\" data-gloss-lang=\"en\" href=\"https://www.cancer.gov/publications/dictionaries/cancer-terms/def/509341\">Tamoxifen</a>&nbsp;and <a data-gloss-id=\"572250\" data-gloss-dictionary=\"Cancer.gov\" data-gloss-audience=\"Patient\" data-gloss-lang=\"en\" href=\"https://www.cancer.gov/publications/dictionaries/cancer-terms/def/572250\">raloxifene</a>&nbsp;are approved by the U.S.&nbsp;Food and Drug Administration (FDA) to reduce breast cancer risk in women who, based on their personal and <a data-gloss-id=\"642015\" data-gloss-dictionary=\"Cancer.gov\" data-gloss-audience=\"Patient\" data-gloss-lang=\"en\" href=\"https://www.cancer.gov/publications/dictionaries/cancer-terms/def/642015\">family medical history</a>, have an increased risk of breast cancer. Whether these medications can be used to prevent breast cancer in women with <a data-gloss-id=\"45098\" data-gloss-dictionary=\"Cancer.gov\" data-gloss-audience=\"Patient\" data-gloss-lang=\"en\" href=\"https://www.cancer.gov/publications/dictionaries/cancer-terms/def/45098\">inherited</a> harmful mutations in <a data-gloss-id=\"46047\" data-gloss-dictionary=\"Cancer.gov\" data-gloss-audience=\"Patient\" data-gloss-lang=\"en\" href=\"https://www.cancer.gov/publications/dictionaries/cancer-terms/def/46047\"><em>BRCA1</em></a>, <a data-gloss-id=\"46742\" data-gloss-dictionary=\"Cancer.gov\" data-gloss-audience=\"Patient\" data-gloss-lang=\"en\" href=\"https://www.cancer.gov/publications/dictionaries/cancer-terms/def/46742\"><em>BRCA2</em></a>, or other genes associated with breast cancer risk is not yet clear (<a href=\"#r18\">18</a>). However, tamoxifen may lower the risk of contralateral breast cancer among <em>BRCA1</em> and <em>BRCA2</em> variant carriers previously diagnosed with breast cancer (<a href=\"#r19\">19</a>).</li> \n       </ul> \n      </div> \n     </div> \n    </section> \n    <section itemscope=\"\" itemprop=\"mainEntity\" itemtype=\"https://schema.org/Question\" aria-labelledby=\"what-can-people-at-very-high-risk-of-ovarian-cancer-do-to-reduce-their-risk\"> \n     <h2 itemprop=\"name\"> <p>What can people at very high risk of ovarian cancer do to reduce their risk?&nbsp;</p> </h2> \n     <div itemscope itemprop=\"acceptedAnswer\" itemtype=\"https://schema.org/Answer\"> \n      <div itemprop=\"text\"> \n       <p>Risk-reducing <a data-gloss-id=\"46569\" data-gloss-dictionary=\"Cancer.gov\" data-gloss-audience=\"Patient\" data-gloss-lang=\"en\" href=\"https://www.cancer.gov/publications/dictionaries/cancer-terms/def/46569\">salpingo-oophorectomy</a> greatly reduces the risk of ovarian cancer and is the most effective approach. However, it has serious <a data-gloss-id=\"46580\" data-gloss-dictionary=\"Cancer.gov\" data-gloss-audience=\"Patient\" data-gloss-lang=\"en\" href=\"https://www.cancer.gov/publications/dictionaries/cancer-terms/def/46580\">side effects</a>, such as inducing <a data-gloss-id=\"449953\" data-gloss-dictionary=\"Cancer.gov\" data-gloss-audience=\"Patient\" data-gloss-lang=\"en\" href=\"https://www.cancer.gov/publications/dictionaries/cancer-terms/def/449953\">early menopause</a> in premenopausal women. Since many ovarian cancers are thought to start in the <a data-gloss-id=\"45687\" data-gloss-dictionary=\"Cancer.gov\" data-gloss-audience=\"Patient\" data-gloss-lang=\"en\" href=\"https://www.cancer.gov/publications/dictionaries/cancer-terms/def/45687\">fallopian tubes</a>, researchers are investigating the use of just salpingectomy to see if this also reduces the risk of ovarian cancer while sparing women from early menopause. However, this is not yet an option in clinical practice.</p> \n       <p>Another potential option is <a href=\"https://www.cancer.gov/about-cancer/causes-prevention/risk/hormones/oral-contraceptives-fact-sheet\">the use of oral contraceptives</a>. Studies have consistently shown that women who have ever used <a data-gloss-id=\"443306\" data-gloss-dictionary=\"Cancer.gov\" data-gloss-audience=\"Patient\" data-gloss-lang=\"en\" href=\"https://www.cancer.gov/publications/dictionaries/cancer-terms/def/443306\">oral contraceptives</a> have a 30% to 50% lower risk of ovarian cancer than women who have never used oral contraceptives (<a href=\"#r20\">20</a>\u2013<a href=\"#r22\">22</a>). A reduction in ovarian cancer risk with use of oral contraceptives has been seen not just among women in general but also among women who carry a harmful variant in the <em>BRCA1</em> or<em> BRCA2</em> gene (<a href=\"#r23\">23</a>\u2013<a href=\"#r25\">25</a>).</p> \n       <p>These hormone-containing medications are thought to reduce the risk of ovarian cancer by preventing <a data-gloss-id=\"44933\" data-gloss-dictionary=\"Cancer.gov\" data-gloss-audience=\"Patient\" data-gloss-lang=\"en\" href=\"https://www.cancer.gov/publications/dictionaries/cancer-terms/def/44933\">ovulation</a>, which reduces exposure to naturally occurring female hormones that fuel the growth of ovarian cancer cells.</p> \n      </div> \n     </div> \n    </section> \n    <section itemscope=\"\" itemprop=\"mainEntity\" itemtype=\"https://schema.org/Question\" aria-labelledby=\"does-health-insurance-cover-the-cost-of-risk-reducing-surgery\"> \n     <h2 itemprop=\"name\"> <p>Does health insurance cover the cost of risk-reducing surgery?</p> </h2> \n     <div itemscope itemprop=\"acceptedAnswer\" itemtype=\"https://schema.org/Answer\"> \n      <div itemprop=\"text\"> \n       <p>Many health insurance companies have official policies about whether and under what conditions they will pay for risk-reducing surgeries for breast and ovarian cancer risk reduction. However, the criteria used for considering these procedures as medically necessary may vary among insurance companies. Some insurance companies may require a <a data-gloss-id=\"774692\" data-gloss-dictionary=\"Cancer.gov\" data-gloss-audience=\"Patient\" data-gloss-lang=\"en\" href=\"https://www.cancer.gov/publications/dictionaries/cancer-terms/def/774692\">second opinion</a> or a letter of medical necessity from the <a data-gloss-id=\"650566\" data-gloss-dictionary=\"Cancer.gov\" data-gloss-audience=\"Patient\" data-gloss-lang=\"en\" href=\"https://www.cancer.gov/publications/dictionaries/cancer-terms/def/650566\">health care provider</a> before they will approve coverage of any surgical procedure. A person who is considering risk-reducing surgery should discuss insurance coverage issues with their doctor and insurance company before choosing to have the surgery.</p> \n      </div> \n     </div> \n    </section> \n    <section itemscope=\"\" itemprop=\"mainEntity\" itemtype=\"https://schema.org/Question\" aria-labelledby=\"who-should-a-person-talk-to-when-considering-surgery-to-reduce-their-risk-of-breast-cancer\"> \n     <h2 itemprop=\"name\"> <p>Who should a person talk to when considering surgery to reduce their risk of breast cancer?</p> </h2> \n     <div itemscope itemprop=\"acceptedAnswer\" itemtype=\"https://schema.org/Answer\"> \n      <div itemprop=\"text\"> \n       <p>If someone has a strong <a data-gloss-id=\"302456\" data-gloss-dictionary=\"Cancer.gov\" data-gloss-audience=\"Patient\" data-gloss-lang=\"en\" href=\"https://www.cancer.gov/publications/dictionaries/cancer-terms/def/302456\">family history</a> of breast cancer, ovarian cancer, or both, they and other members of their family should talk with a <a data-gloss-id=\"794108\" data-gloss-dictionary=\"Cancer.gov\" data-gloss-audience=\"Patient\" data-gloss-lang=\"en\" href=\"https://www.cancer.gov/publications/dictionaries/cancer-terms/def/794108\">genetic counselor</a> to understand whether they are truly at very high risk (that is, are likely to have a harmful variant in <em>BRCA1</em>, <em>BRCA2</em>, or another gene linked to breast cancer). A genetic counselor or other health care provider trained in genetics can review the family\u2019s risks of disease and help family members obtain <a href=\"https://www.cancer.gov/about-cancer/causes-prevention/genetics/genetic-testing-fact-sheet\">genetic testing for harmful changes in cancer-predisposing genes</a>, if appropriate.</p> \n       <p>The decision to have any surgery to reduce the risk of breast cancer is a major one. Someone who is at high risk of breast cancer may wish to get a <a data-gloss-id=\"774692\" data-gloss-dictionary=\"Cancer.gov\" data-gloss-audience=\"Patient\" data-gloss-lang=\"en\" href=\"https://www.cancer.gov/publications/dictionaries/cancer-terms/def/774692\">second opinion</a> on risk-reducing surgery as well as on alternatives to surgery. For more information on getting a second opinion, see NCI's <a href=\"https://www.cancer.gov/about-cancer/managing-care/services\">Finding Health Care Services</a> page.</p> \n       <p>A person who is considering risk-reducing mastectomy may also want to talk with a breast surgeon and a surgeon who specializes in <a href=\"https://www.cancer.gov/types/breast/treatment/surgery/breast-reconstruction\" data-entity-type=\"node\" data-entity-uuid=\"c8462e9d-fc81-4edf-9575-5d9bbfa0b1f6\" data-entity-substitution=\"canonical\">breast reconstruction</a>. Other health care professionals, including a breast health specialist, medical social worker, or cancer clinical psychologist or psychiatrist, can also help someone consider their options for reducing their risk of breast cancer.</p> \n      </div> \n     </div> \n    </section> \n   </div> \n  </div> \n  <div> \n   <div> \n    <div> \n     <h2> Selected References </h2> \n     <ol> \n      <li> <p>Carbine NE, Lostumbo L, Wallace J, Ko H. Risk-reducing mastectomy for the prevention of primary breast cancer. <em>Cochrane Database of Systematic Reviews</em> 2018; 4(4):CD002748.</p> <a href=\"https://www.ncbi.nlm.nih.gov/pubmed/29620792\">[PubMed Abstract]</a> </li> \n      <li> <p>Mai PL, Miller A, Gail MH, et al. Risk-reducing salpingo-oophorectomy and breast cancer risk reduction in the Gynecologic Oncology Group Protocol-0199 (GOG-0199). <em>JNCI Cancer Spectrum</em> 2019; 4(1):pkz075.&nbsp;</p> <a href=\"https://www.ncbi.nlm.nih.gov/pubmed/32337492\">[PubMed Abstract]</a> </li> \n      <li> <p>Conduit C, Milne RL, Friedlander ML, Phillips KA. Bilateral salpingo-oophorectomy and breast cancer risk for <em>BRCA1</em> and <em>BRCA2</em> mutation carriers: Assessing the evidence. <em>Cancer Prevention Research </em>2021; 14(11):983\u2013994.</p> <a href=\"https://www.ncbi.nlm.nih.gov/pubmed/34348913\">[PubMed Abstract]</a> </li> \n      <li> <p>Choi YH, Terry MB, Daly MB, et al. Association of risk-reducing salpingo-oophorectomy with breast cancer risk in women with <em>BRCA1</em> and <em>BRCA2</em> pathogenic variants.<em> JAMA Oncology</em> 2021; 7(4):585\u2013592.</p> <a href=\"https://www.ncbi.nlm.nih.gov/pubmed/33630024\">[PubMed Abstract]</a> </li> \n      <li> <p>Gaba F, Blyuss O, Tan A, et al. Breast cancer risk and breast-cancer-specific mortality following risk-reducing salpingo-oophorectomy in BRCA carriers: A systematic review and meta-analysis. <em>Cancers</em> 2023; 15(5):1625.&nbsp;</p> <a href=\"https://www.ncbi.nlm.nih.gov/pubmed/36900415\">[PubMed Abstract]</a> </li> \n      <li> <p>Hartmann LC, Schaid DJ, Woods JE, et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. <em>New England Journal of Medicine</em> 1999; 340(2):77-84.</p> <a href=\"https://www.ncbi.nlm.nih.gov/pubmed/9887158\">[PubMed Abstract]</a> </li> \n      <li> <p>Domchek SM, Friebel TM, Singer CF, et al. Association of risk-reducing surgery in <em>BRCA1</em> or <em>BRCA2</em> mutation carriers with cancer risk and mortality. <em>JAMA</em> 2010; 304(9):967\u2013975.</p> <a href=\"https://www.ncbi.nlm.nih.gov/pubmed/20810374\">[PubMed Abstract]</a> </li> \n      <li> <p>Rebbeck TR, Friebel T, Lynch HT, et al. Bilateral prophylactic mastectomy reduces breast cancer risk in <em>BRCA1</em> and <em>BRCA2</em> mutation carriers: The PROSE Study Group. <em>Journal of Clinical Oncology</em> 2004; 22(6):1055-1062.</p> <a href=\"https://www.ncbi.nlm.nih.gov/pubmed/14981104\">[PubMed Abstract]</a> </li> \n      <li> <p>Meijers-Heijboer H, van Geel B, van Putten WL, et al. Breast cancer after prophylactic bilateral mastectomy in women with a <em>BRCA1</em> or <em>BRCA2</em> mutation. <em>New England Journal of Medicine</em> 2001; 345(3):159-164.</p> <a href=\"https://www.ncbi.nlm.nih.gov/pubmed/11463009\">[PubMed Abstract]</a> </li> \n      <li> <p>King TA, Sakr R, Patil S, et al. Clinical management factors contribute to the decision for contralateral prophylactic mastectomy. <em>Journal of Clinical Oncology</em> 2011; 29(16):2158-2164.</p> <a href=\"https://www.ncbi.nlm.nih.gov/pubmed/21464413\">[PubMed Abstract]</a> </li> \n      <li> <p>Cuzick J, Sestak I, Baum M, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. <em>Lancet Oncology</em> 2010; 11(12):1135\u20131141.</p> <a href=\"https://www.ncbi.nlm.nih.gov/pubmed/21087898\">[PubMed Abstract]</a> </li> \n      <li> <p>Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. <em>Lancet</em> 2005; 365(9472):1687\u20131717.</p> <a href=\"https://www.ncbi.nlm.nih.gov/pubmed/15894097\">[PubMed Abstract]</a> </li> \n      <li> <p>Martelli G, Barretta F, Vernieri C, et al. Prophylactic salpingo-oophorectomy and survival after BRCA1/2 breast cancer resection.<em> JAMA Surgery</em> 2023; 158(12):1275\u20131284.</p> <a href=\"https://www.ncbi.nlm.nih.gov/pubmed/37792368\">[PubMed Abstract]</a> </li> \n      <li> <p>Singletary S. Techniques in surgery: therapeutic and prophylactic mastectomy. In: Harris J, Lippman M, Morrow M, Osborn C, eds. <em>Diseases of the Breast</em>. 3rd ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2004.</p> </li> \n      <li> <p>Brandberg Y, Sandelin K, Erikson S, et al. Psychological reactions, quality of life, and body image after bilateral prophylactic mastectomy in women at high risk for breast cancer: A prospective 1-year follow-up study. <em>Journal of Clinical Oncology &nbsp;</em>2008; 26(24):3943-3949.</p> <a href=\"https://www.ncbi.nlm.nih.gov/pubmed/18711183\">[PubMed Abstract]</a> </li> \n      <li> <p>Frost MH, Hoskin TL, Hartmann LC, et al. Contralateral prophylactic mastectomy: Long-term consistency of satisfaction and adverse effects and the significance of informed decision-making, quality of life, and personality traits. <em>Annals of Surgical Oncology</em> 2011; 18(11):3110-3116.</p> <a href=\"https://www.ncbi.nlm.nih.gov/pubmed/21947589\">[PubMed Abstract]</a> </li> \n      <li> <p>Saslow D, Boetes C, Burke W, et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. <em>CA: A Cancer Journal for Clinicians</em> 2007; 57(2):75-89.</p> <a href=\"https://www.ncbi.nlm.nih.gov/pubmed/17392385\">[PubMed Abstract]</a> </li> \n      <li> <p>Singer CF. Nonsurgical prevention strategies in <em>BRCA1</em> and <em>BRCA2</em> mutation carriers. <em>Breast Care</em> 2021; 16(2):144\u2013148.</p> <a href=\"https://www.ncbi.nlm.nih.gov/pubmed/34012368\">[PubMed Abstract]</a> </li> \n      <li> <p>Phillips KA, Milne RL, Rookus MA, et al. Tamoxifen and risk of contralateral breast cancer for <em>BRCA1</em> and <em>BRCA2 </em>mutation carriers. <em>Journal of Clinical Oncology</em> 2013; 31(25):3091-3099.</p> <a href=\"https://www.ncbi.nlm.nih.gov/pubmed/23918944\">[PubMed Abstract]</a> </li> \n      <li> <p>IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Combined Estrogen\u2013Progestogen Contraceptives and Combined Estrogen\u2013Progestogen Menopausal Therapy. Lyon (FR): International Agency for Research on Cancer; 2007. (IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, No. 91.) Available from: <a href=\"https://www.ncbi.nlm.nih.gov/books/NBK321672/\">https://www.ncbi.nlm.nih.gov/books/NBK321672/</a></p> </li> \n      <li> <p>Havrilesky LJ, Moorman PG, Lowery WJ, et al. Oral contraceptive pills as primary prevention for ovarian cancer: A systematic review and meta-analysis. <em>Obstetrics and Gynecology</em> 2013; 122(1):139\u2013147.</p> <a href=\"https://www.ncbi.nlm.nih.gov/pubmed/23743450\">[PubMed Abstract]</a> </li> \n      <li> <p>Wentzensen N, Poole EM, Trabert B, et al. Ovarian cancer risk factors by histologic subtype: An analysis from the Ovarian Cancer Cohort Consortium. <em>Journal of Clinical Oncology</em> 2016; 34(24):2888\u20132898.</p> <a href=\"https://www.ncbi.nlm.nih.gov/pubmed/27325851\">[PubMed Abstract]</a> </li> \n      <li> <p>Huber D, Seitz S, Kast K, Emons G, Ortmann O. Use of oral contraceptives in BRCA mutation carriers and risk for ovarian and breast cancer: A systematic review. <em>Archives of Gynecology and Obstetrics</em> 2020; 301(4):875\u2013884.</p> <a href=\"https://www.ncbi.nlm.nih.gov/pubmed/32140806\">[PubMed Abstract]</a> </li> \n      <li> <p>van Bommel MHD, IntHout J, Veldmate G, et al. Contraceptives and cancer risks in BRCA1/2 pathogenic variant carriers: A systematic review and meta-analysis. <em>Human Reproduction Update </em>2023; 29(2):197\u2013217.</p> <a href=\"https://www.ncbi.nlm.nih.gov/pubmed/36383189\">[PubMed Abstract]</a> </li> \n      <li> <p>Schrijver LH, Antoniou AC, Olsson H, et al. Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers: An international cohort study. <em>American Journal of Obstetrics and Gynecology</em> 2021; 225(1):51.e1\u201351.e17.</p> <a href=\"https://www.ncbi.nlm.nih.gov/pubmed/33493488\">[PubMed Abstract]</a> </li> \n     </ol> \n    </div> \n   </div> \n   <aside> \n    <h2>Related Resources</h2> \n    <ul> \n     <li> \n      <div> \n       <a href=\"https://www.cancer.gov/about-cancer/causes-prevention/genetics/brca-fact-sheet\">BRCA Gene Changes: Cancer Risk and Genetic Testing</a> \n      </div> </li> \n     <li> \n      <div> \n       <a href=\"https://www.cancer.gov/types/breast/treatment/surgery/breast-reconstruction\">Breast Reconstruction After Mastectomy</a> \n      </div> </li> \n     <li> \n      <div> \n       <a href=\"https://www.cancer.gov/about-cancer/causes-prevention/genetics/genetic-testing-fact-sheet\">Genetic Testing for Inherited Cancer Risk</a> \n      </div> </li> \n     <li> \n      <div> \n       <a href=\"https://www.cancer.gov/types/breast/screening/mammograms\">Mammograms</a> \n      </div> </li> \n     <li> \n      <div> \n       <a href=\"https://www.cancer.gov/about-cancer/causes-prevention/risk/hormones/oral-contraceptives-fact-sheet\">Oral Contraceptives and Cancer Risk</a> \n      </div> </li> \n     <li> \n      <div> \n       <a href=\"https://www.cancer.gov/types/breast/hp/breast-ovarian-genetics-pdq\">Genetics of Breast and Gynecologic Cancers (PDQ\u00ae)\u2013Health Professional Version</a> \n      </div> </li> \n    </ul> \n   </aside> \n   <div> \n    <p>Posted: <time datetime=\"2024-07-03T12:00:00Z\">Wed, 07/03/2024 - 12:00</time> </p> \n    <p>Updated: <time datetime=\"2025-12-02T12:00:00Z\">Tue, 12/02/2025 - 12:00</time> </p> \n    <p>Reviewed: <time datetime=\"2024-06-26T12:00:00Z\">Wed, 06/26/2024 - 12:00</time> </p> \n   </div> \n   <span>This content is provided by the National Cancer Institute (<a href=\"http://www.cancer.gov\">www.cancer.gov</a>)</span> \n  </div> \n </div>\n <script type=\"application/ld+json\">{\"@context\":\"http://schema.org\",\"@type\":\"Article\",\"headline\":\"Surgery to Reduce the Risk of Breast Cancer\",\"datePublished\":\"2013-00-06T15:00:07Z\",\"description\":\"A fact sheet that describes mastectomy and salpingo-oophorectomy, two surgeries that may be used to reduce breast cancer risk in women at very high risk, and nonsurgical options.\",\"about\":\"cancer, prevention, risk, reduce, breast, ovarian, surgery, reconstruction, mastectomy, BRCA1, BRCA2, prophylactic, subcutaneous, 7.5, contralateral, oophorectomy, PTEN, TP53, ovary, risk-reducing\",\"audience\":\"\",\"dateCreated\":\"2013-00-06T15:00:07Z\",\"dateModified\":\"2019-41-05T19:41:37Z\",\"sourceOrganization\":\"National Cancer Institute\"}</script>\n</body><div class='syndicate'><span><Strong>Syndicated Content Details:</strong></span><br/><span>Source URL: <a href='https://www.cancer.gov/node/14381/syndication'>https://www.cancer.gov/node/14381/syndication</a></span><br/><span>Source Agency: <a href='http://www.cancer.gov'>National Cancer Institute (NCI)</a></span><br/><span>Captured Date: 2013-12-06 15:00:07.0</span><br/></div><iframe src=\"//www.googletagmanager.com/ns.html?id=GTM-KT9TM9&mediaId=1736&mediaType=html&sourceUrl=https%3A%2F%2Fwww.cancer.gov%2Fnode%2F14381%2Fsyndication&userId=-1&sourceId=5&sourceAcronym=NCI&campaignId=-1&campaignName=null&languageId=1&isoCode=eng\" height=\"0\" width=\"0\" style=\"display:none;visibility:hidden\"></iframe><noscript><iframe src=\"//www.googletagmanager.com/ns.html?id=GTM-KT9TM9&mediaId=1736&mediaType=html&sourceUrl=https%3A%2F%2Fwww.cancer.gov%2Fnode%2F14381%2Fsyndication&userId=-1&sourceId=5&sourceAcronym=NCI&campaignId=-1&campaignName=null&languageId=1&isoCode=eng\" height=\"0\" width=\"0\" style=\"display:none;visibility:hidden\"></iframe></noscript>","description":"A fact sheet that describes mastectomy and salpingo-oophorectomy, two surgeries that may be used to reduce breast cancer risk in women at very high risk, and nonsurgical options.","id":1736,"mediaType":"Html","name":"Surgery to Reduce the Risk of Breast Cancer","sourceUrl":"https://www.cancer.gov/node/14381/syndication"}]}